This website is intended for healthcare professionals only.

Newsletter          
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Gastroenterology

Bowel cancer rates increasing across Europe
Bowel cancer rates increasing across Europe
Ustekinumab shows sustained efficacy in improving remission rates in Crohn’s disease over three years
Ustekinumab shows sustained efficacy in improving remission rates in Crohn’s disease over three years
Adalimumab biosimilar Imraldi launched in European Union
Adalimumab biosimilar Imraldi launched in European Union
EC approves early dose optimisation of Simponi for ulcerative colitis patients
EC approves early dose optimisation of Simponi for ulcerative colitis patients
Children in Scotland first in the UK to be treated with teduglutide by the NHS
Children in Scotland first in the UK to be treated with teduglutide by the NHS
Biosimilar infliximab comparable to reference product and adalimumab in real-world study
Biosimilar infliximab comparable to reference product and adalimumab in real-world study
Bowel Cancer UK identifies critical research gaps
Bowel Cancer UK identifies critical research gaps
One-year results for biosimilar infliximab switching study in Crohn’s disease
One-year results for biosimilar infliximab switching study in Crohn’s disease
Symptom improvement in moderately to severely active Crohn’s disease with ustekinumab
Symptom improvement in moderately to severely active Crohn’s disease with ustekinumab
Positive CHMP opinion for adalimumab biosimilar
Positive CHMP opinion for adalimumab biosimilar
Eluxadoline receives final approval from NICE for the treatment of IBS with diarrhoea
Eluxadoline receives final approval from NICE for the treatment of IBS with diarrhoea
Biosimilar adalimumab and infliximab accepted for regulatory review by the EMA
Biosimilar adalimumab and infliximab accepted for regulatory review by the EMA


Popular articles

Pholcodine containing cough and cold medicines withdrawn from UK market
Ketogenic diet linked to higher LDL cholesterol and increased risk of adverse cardiac events
DNA damage to oral cells similar in never smoking vapers and current smokers
Oral PCSK9 inhibitor significantly lowers LDL cholesterol in adults with hypercholesterolaemia
Both controlled and uncontrolled hypertension in obese patients increase all-cause mortality risk




 

Download Hospital Healthcare Europe free app

Download our app from the Apple App Store Download our app from Google Play

In official association with

HOPE Logo Footer

© Cogora 2023
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora